0000000000243515

AUTHOR

Antonio Gnoni

showing 5 related works from this author

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey

2014

BackgroundBone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.ResultsThe median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. The median time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bone metastases. Spine was the most common site of bon…

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsGastroenterology and HepatologyBiochemistryGastroenterologyBone and BonesMetastasisInternal medicineMedicine and Health SciencesmedicineCarcinomaHumansAged; Bone Neoplasms; Bone and Bones; Carcinoma Hepatocellular; Female; Humans; Italy; Liver; Liver Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Survival analysisAgedPharmacologyMultidisciplinarybusiness.industryCarcinomaLiver NeoplasmsQRBone metastasisHepatocellularBone fractureMiddle AgedBisphosphonatemedicine.diseaseSurvival Analysiszoledronic acidHepatocellular Carcinomaskeletal-related eventsSurgeryZoledronic acidOncologyItalyLiverAgricultural and Biological Sciences (all)Quality of LifeMedicineFemalebusinessResearch Articlemedicine.drug
researchProduct

Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets?

2015

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and few chemotherapeutic choices. MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of around 22 nucleotides involved in the pathogenic mechanisms of carcinogenesis and metastasis. They have been studied in many tumors in order to identify potential diagnostic, prognostic or therapeutic targets. In the current literature, many studies have analyzed the role of miRNAs in PDAC. In fact, the absence of appropriate biomarkers, the difficultly of early detection of this tumor, and the lack of effective chemotherapy in patients with unresectable disease have focused attention on miRNAs as new, i…

Maleendocrine system diseasesPrognosiSettore MED/06 - Oncologia MedicaMice NudeReviewDiseaseAdenocarcinomaMalignancymedicine.disease_causeMetastasisMicemicroRNABiomarkers TumorCarcinomamedicineAnimalsHumansmiRNAbiomarkers; miRNAs; pancreatic adenocarcinoma; prognosis; therapyAnimalbusiness.industryPancreatic NeoplasmbiomarkersMicroRNABiomarkerPrognosismedicine.diseasePhenotypedigestive system diseasesPancreatic NeoplasmsGene Expression Regulation NeoplasticMicroRNAsPhenotypeBiomarkers; miRNAs; Pancreatic adenocarcinoma; Prognosis; Therapy; Adenocarcinoma; Animals; Biomarkers Tumor; Carcinoma Pancreatic Ductal; Female; Gene Expression Regulation Neoplastic; Humans; Male; Mice; Mice Nude; MicroRNAs; Pancreatic Neoplasms; Phenotype; Prognosis; OncologyOncologymiRNAsImmunologyCancer researchAdenocarcinomaFemaleTherapybusinessCarcinogenesisPancreatic adenocarcinomaCarcinoma Pancreatic DuctalHuman
researchProduct

Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients

2011

Fluoropyrimidines and oxaliplatin continued to be the mainstay of therapeutic regimens in the treatment of colorectal cancer (CRC). For this reason, pharmacokinetic and metabolism of these drugs were analyzed and the identification of accurate and validated predictive, prognostic and toxicity markers became necessary to develop an effective therapy adapted to the patient's molecular profile, while minimizing life-threatening toxicities. In this review, we discuss literature data, defining predictive and prognostic markers actually identified in the treatment of CRC. We analyzed predictive markers of fluoropyrimidines effectiveness, principally for 5-Fluorouracil (5-FU) and also for oral flu…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia Medica5-FluorouracilPredictive markerClinical BiochemistryAntineoplastic AgentsPharmacologyThymidylate synthaseXRCC1Internal medicinemedicineDihydropyrimidine dehydrogenaseBiomarkers TumorHumans5-Fluorouracil; Dihydropyrimidine dehydrogenase; Glutathione S-transferase; Nucleotide excision repair; Oxaliplatin; Predictive marker; Thymidylate Synthase; Toxicity marker; Pharmacology; Clinical BiochemistryPharmacologyPredictive markerbiologyMicrosatellite instabilityThymidylate Synthasemedicine.diseaseToxicity markerOxaliplatinGlutathione S-transferaseOxaliplatinNucleotide excision repairPyrimidinesbiology.proteinERCC1Colorectal NeoplasmsDihydropyrimidine dehydrogenasemedicine.drug
researchProduct

Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?

2015

Introduction: Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC). Alternative first- and second-line treatments are a significant unmet medical need, and several biologic agents have been tested in recent years, with poor results. Therefore, angiogenic pathways and the cytokine cascade remain possible targets in HCC. Recent studies suggest a role of epigenetic processes, associated with the initiation and development of HCC. In this field, DNA methylation, micro-RNAs (miRNAs) and tumor microenvironment cells became a possible new target for HCC treatment. Areas covered: This review explains the possible role of DNA methylation and histone deacetylase inhibito…

Settore MED/06 - Oncologia MedicaClinical BiochemistrytivantinibEpigenesis GeneticAntineoplastic Agentchemistry.chemical_compoundHistone Deacetylase InhibitorDrug DiscoveryTumor MicroenvironmentMolecular Targeted TherapyplateletmicroRNALiver Neoplasmshepatocellular carcinomaSorafenibVEGFLiver NeoplasmHepatocellular carcinomaDNA methylationMolecular MedicineepigeneticHumanmedicine.drugPhenylurea CompoundSorafenibNiacinamideCarcinoma HepatocellularAntineoplastic AgentsBiologymicroRNAmedicineAnimalsHumansEpigeneticsTivantinibPharmacologyTumor microenvironmentAnimalDrug Discovery3003 Pharmaceutical SciencePhenylurea CompoundsDNA Methylationmedicine.diseasedigestive system diseasesHistone Deacetylase InhibitorsMicroRNAschemistryDrug DesignImmunologyCancer researchHistone deacetylaseExpert opinion on therapeutic targets
researchProduct

Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a…

2022

The progressive improvement of lymphoma treatment has led to an important prolongation of patient survival and life expectancy. The principal international scientific societies of oncology now therefore recommend that long-term survivors of lymphoma join fertility programs. Specifically, fertile-age patients should be assisted by a multidisciplinary team, including specialists dedicated to fertility preservation in oncology, in order to support the completion of their reproductive project. In the general population, the use of Myo-Inositol and D-Chiro-Inositol (MI/DCI) has been demonstrated to be an effective choice to treat ovarian dysfunctions, with a consequent improvement in reproductiv…

reproductive outcomesfertility preservationhealth promotionprecision medicineMedicine (miscellaneous)lymphomaprecision medicine; health promotion; Inositol; lymphoma; fertility preservation; reproductive outcomesSettore MED/40 - Ginecologia E OstetriciaInositolInositol; fertility preservation; health promotion; lymphoma; precision medicine; reproductive outcomesJournal of personalized medicine
researchProduct